Zacks Research Issues Pessimistic Outlook for PLX Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Investment analysts at Zacks Research dropped their Q3 2026 earnings per share estimates for Protalix BioTherapeutics in a report released on Thursday, August 13th. Zacks Research analyst J. Vandermosten now expects that the company will post earnings of ($0.05) per share for the quarter, down from their previous forecast of ($0.03). The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics’ Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at $0.19 EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.02 EPS.

Protalix BioTherapeutics Stock Up 0.4%

Shares of PLX stock opened at $2.35 on Thursday. The stock has a 50-day simple moving average of $2.31 and a 200 day simple moving average of $2.36. Protalix BioTherapeutics has a fifty-two week low of $1.48 and a fifty-two week high of $3.19. The stock has a market capitalization of $189.34 million, a P/E ratio of -18.08 and a beta of 0.02.

Institutional Investors Weigh In On Protalix BioTherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in shares of Protalix BioTherapeutics during the fourth quarter valued at $26,000. Equitable Holdings Inc. purchased a new position in Protalix BioTherapeutics in the 2nd quarter worth about $31,000. Ieq Capital LLC purchased a new position in Protalix BioTherapeutics in the 2nd quarter worth about $32,000. Bank of America Corp DE raised its holdings in Protalix BioTherapeutics by 364,766.7% during the 2nd quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock worth $32,000 after buying an additional 21,886 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Protalix BioTherapeutics by 126.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock worth $34,000 after buying an additional 8,498 shares during the period. 16.53% of the stock is owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.